STAAR Surgical (STAA)
Builds implantable lenses used in refractive surgery for vision correction.
Something off on this page? Send us feedback.
Sells EVO and Visian implantable Collamer lenses for refractive surgery, with revenue now centered on ICL products after cataract lenses were phased out. Commercial performance is international and shaped by China distributor inventory, surgeon training, regulatory approvals, and competition from laser vision-correction procedures.
Designs, manufactures, and sells implantable Collamer lenses and delivery systems for ophthalmic surgery, with current revenue concentrated in EVO and Visian ICL products for refractive correction. Cataract IOLs have been phased out as the product focus narrowed around ICLs.
Sells through an international refractive-surgery model that depends on trained surgeons, patient awareness, distributors in key markets, and regulatory approvals for each ICL variant. China, Japan, South Korea, and the United States are central disclosed markets, with China distributor inventory driving a recent reset and rebound.
Competes mainly against laser refractive procedures rather than close-copy lens products. Governance is also in transition after the failed Alcon merger process and the appointment of interim co-CEOs.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Jefferies | Reiterate | Rating: —Target: $28 | Target: $23 |
| Aug 17, 2026 | UBS | Target | Target: $19 | Target: $28 |
| Aug 13, 2026 | Jefferies | Reiterate | Rating: —Target: $60 | Target: $28 |
| Aug 13, 2026 | William Blair | Target | Target: $45.03 | Target: $33 |
| Aug 13, 2026 | UBS | Reiterate | Rating: —Target: — | Target: $19 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 3, 2026Cash & short-term investments $181.5M · Total debt $35.9M · Total assets $475.2M · Shareholders' equity $365.4M
- Revenue
- $93.5M
- Operating income
- $10.1M
- Net income
- $8.1M
No dividends on record.
| Institutions | 111.00% | 55.66M shares | |
|---|---|---|---|
| 211 holders · as of Jun 30, 2026 | |||
| Insiders | 0.97% | 488.8K shares | |
| 12 holders · as of Aug 18, 2026 | |||
| Adds to | 111.97% | ||
50.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 111.97%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Broadwood Capital IncInstitution | 32.16% | 16.12M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 13.42% | 6.73M | as of Jun 30, 2026 |
Baillie Gifford & Co (Scottish partnership)Institution | 11.03% | 5.53M | filed Jan 26, 2022 |
Madison Avenue Partners, LPInstitution | 8.33% | 4.18M | as of Jun 30, 2026 |
Yunqi Capital LtdInstitution | 6.50% | 3.26M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 11, 2026 | Broadwood Partners, L.P. | director, 10 percent owner: | +54,764 | $17.52 |
| Mar 12, 2026 | Broadwood Partners, L.P. | director, 10 percent owner: | +299,432 | $18.12 |
| Mar 13, 2026 | Broadwood Partners, L.P. | director, 10 percent owner: | +316,017 | $18.62 |
| Jan 9, 2026 | Broadwood Partners, L.P. | 10 percent owner | +27,485 | $22.05 |
| Jan 6, 2026 | Broadwood Partners, L.P. | 10 percent owner | +336,946 | $21.62 |
- Alcon
Broad refractive laser substitute through WaveLight LASIK systems
- Bausch + Lomb
TENEO excimer LASIK platform and broad eye-health channel overlap
- Johnson & Johnson
LASIK and PRK overlap through iDESIGN and STAR S4 IR systems
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| STAAR Surgical | $20.31 | −1.65% | $1.03B | 258.1 | 35.2 | 3.0 | +111.0% |
| Alcon | $65.41 | −0.27% | $31.99B | 50.5 | 17.2 | 3.0 | +7.5% |
| Bausch + Lomb | $17.23 | −0.52% | $6.19B | — | 17.3 | 1.2 | +9.1% |
| Johnson & Johnson | $270.67 | +0.55% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Median | 40.8 | 17.3 | 3.0 | +7.5% |